Literature DB >> 7506638

Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells.

S Akinaga1, K Nomura, K Gomi, M Okabe.   

Abstract

UCN-01 (7-hydroxy-staurosporine), a selective inhibitor of protein kinase C (PKC), was shown to exhibit antitumor activity in murine and human tumor cell lines in vitro and in vivo. On the other hand, staurosporine, a non-selective protein kinase inhibitor, was not shown to exert antitumor activity in vivo despite its potent antiproliferative activity in vitro. To compare the modes of action of UCN-01 and staurosporine in vitro, the effects of both drugs on the cell cycle progression of human epidermoid carcinoma A431 cells were examined by flow cytometry using propidium iodide (PI) staining. At 50% growth inhibitory concentrations, both UCN-01 and staurosporine induced G1 phase accumulation in the cell cycle. At 80% growth inhibitory concentrations, UCN-01 also induced preferential G1 phase accumulation, but staurosporine mostly induced G2M phase accumulation. Staurosporine also induced higher DNA ploidy when the cells were exposed to the drug for more than one generation time of A431 cells. An analysis of cell kinetics by 5-bromo-2-deoxyuridine incorporation versus DNA content confirmed that the G1 phase block by UCN-01 and the G1 and G2M phase block by staurosporine at the respective doses, as was the case for PI staining. Additionally, DNA synthesis of the cells, which was determined by the uptake of 3H-TdR, was not suppressed at least 8 h after the treatment with UCN-01. These results suggested that UCN-01 could affect the G1 phase of cell cycle in A431 cells in quite different manners from staurosporine. The G1 phase block induced by UCN-01 might be important for the growth inhibitory activity of UCN-01 against A431 cells in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7506638     DOI: 10.1007/bf00685899

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

Review 1.  Mitogen-activated protein kinases: versatile transducers for cell signaling.

Authors:  S L Pelech; J S Sanghera
Journal:  Trends Biochem Sci       Date:  1992-06       Impact factor: 13.807

2.  Activation of the MAP kinase pathway by the protein kinase raf.

Authors:  L R Howe; S J Leevers; N Gómez; S Nakielny; P Cohen; C J Marshall
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

Review 3.  The cell cycle then and now.

Authors:  M Kirschner
Journal:  Trends Biochem Sci       Date:  1992-08       Impact factor: 13.807

4.  Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes.

Authors:  S Bruno; B Ardelt; J S Skierski; F Traganos; Z Darzynkiewicz
Journal:  Cancer Res       Date:  1992-01-15       Impact factor: 12.701

5.  A candidate protein kinase C gene, PKC1, is required for the S. cerevisiae cell cycle.

Authors:  D E Levin; F O Fields; R Kunisawa; J M Bishop; J Thorner
Journal:  Cell       Date:  1990-07-27       Impact factor: 41.582

6.  In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.

Authors:  D J Giard; S A Aaronson; G J Todaro; P Arnstein; J H Kersey; H Dosik; W P Parks
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

Review 7.  Potent and specific inhibitors of protein kinase C of microbial origin.

Authors:  T Tamaoki; H Nakano
Journal:  Biotechnology (N Y)       Date:  1990-08

8.  Activation of messenger-independent protein kinases in wild-type and phorbol ester-resistant EL4 thymoma cells.

Authors:  K E Meier; K A Licciardi; T A Haystead; E G Krebs
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

Review 9.  Structural and functional diversities of a family of signal transducing protein kinases, protein kinase C family; two distinct classes of PKC, conventional cPKC and novel nPKC.

Authors:  S Ohno; Y Akita; A Hata; S Osada; K Kubo; Y Konno; K Akimoto; K Mizuno; T Saido; T Kuroki
Journal:  Adv Enzyme Regul       Date:  1991

10.  UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities.

Authors:  I Takahashi; Y Saitoh; M Yoshida; H Sano; H Nakano; M Morimoto; T Tamaoki
Journal:  J Antibiot (Tokyo)       Date:  1989-04       Impact factor: 2.649

View more
  14 in total

1.  Dexniguldipine hydrochloride, a protein-kinase-C-specific inhibitor, affects the cell cycle, differentiation, P-glycoprotein levels, and nuclear protein phosphorylation in Friend erythroleukemia cells.

Authors:  K K Patterson; B S Beckman; D M Klotz; C M Mallia; J R Jeter
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism.

Authors:  Y Luo; S K Rockow-Magnone; P E Kroeger; L Frost; Z Chen; E K Han; S C Ng; R L Simmer; V L Giranda
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

Review 3.  Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).

Authors:  M Smith; P T Ho
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein.

Authors:  E Fuse; A Hashimoto; N Sato; H Tanii; T Kuwabara; S Kobayashi; Y Sugiyama
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

5.  Tryptophan residues play an important role in the extraordinarily high affinity binding interaction of UCN-01 to human alpha-1-acid glycoprotein.

Authors:  Masaaki Katsuki; Victor Tuan Giam Chuang; Koji Nishi; Ayaka Suenaga; Masaki Otagiri
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

6.  Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.

Authors:  Antonio Jimeno; Michelle A Rudek; Thomas Purcell; Daniel A Laheru; Wells A Messersmith; Janet Dancey; Michael A Carducci; Sharyn D Baker; Manuel Hidalgo; Ross C Donehower
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-12       Impact factor: 3.333

7.  A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.

Authors:  Paula M Fracasso; Kerry J Williams; Ronald C Chen; Joel Picus; Cynthia X Ma; Matthew J Ellis; Benjamin R Tan; Timothy J Pluard; Douglas R Adkins; Michael J Naughton; Janet S Rader; Matthew A Arquette; James W Fleshman; Allison N Creekmore; Sherry A Goodner; Lisa P Wright; Zhanfang Guo; Christine E Ryan; Yu Tao; Eliane M Soares; Shi-Rong Cai; Li Lin; Janet Dancey; Michelle A Rudek; Howard L McLeod; Helen Piwnica-Worms
Journal:  Cancer Chemother Pharmacol       Date:  2010-08-08       Impact factor: 3.333

8.  Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells.

Authors:  C Courage; R Snowden; A Gescher
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

9.  UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery.

Authors:  S Abe; T Kubota; Y Otani; T Furukawa; M Watanabe; K Kumai; T Akiyama; S Akinaga; M Kitajima
Journal:  Jpn J Cancer Res       Date:  2001-05

10.  Protein kinase C: an attractive target for cancer therapy.

Authors:  Barbara Marengo; Chiara De Ciucis; Roberta Ricciarelli; Maria A Pronzato; Umberto M Marinari; Cinzia Domenicotti
Journal:  Cancers (Basel)       Date:  2011-02-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.